S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
Log in

NYSEAMERICAN:NBY - NovaBay Pharmaceuticals Stock Price, Forecast & News

$0.59
-0.01 (-1.67 %)
(As of 02/24/2020 04:00 PM ET)
Today's Range
$0.57
Now: $0.59
$0.61
50-Day Range
$0.45
MA: $0.68
$1.20
52-Week Range
$0.23
Now: $0.59
$4.04
Volume320,600 shs
Average Volume238,281 shs
Market Capitalization$16.46 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. Read More…

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:NBY
CUSIPN/A
Phone+1-510-8998800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees70
Market Cap$16.46 million
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive NBY News and Ratings via Email

Sign-up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.


NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?

NovaBay Pharmaceuticals shares reverse split on Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) posted its earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.09. The biopharmaceutical company earned $4.09 million during the quarter, compared to analysts' expectations of $4.69 million. View NovaBay Pharmaceuticals' Earnings History.

When is NovaBay Pharmaceuticals' next earnings date?

NovaBay Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for NovaBay Pharmaceuticals.

What price target have analysts set for NBY?

3 brokers have issued 1 year target prices for NovaBay Pharmaceuticals' shares. Their forecasts range from $1.10 to $1.10. On average, they anticipate NovaBay Pharmaceuticals' share price to reach $1.10 in the next year. This suggests a possible upside of 86.4% from the stock's current price. View Analyst Price Targets for NovaBay Pharmaceuticals.

What is the consensus analysts' recommendation for NovaBay Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NovaBay Pharmaceuticals.

Has NovaBay Pharmaceuticals been receiving favorable news coverage?

News coverage about NBY stock has trended neutral recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. NovaBay Pharmaceuticals earned a news impact score of 0.4 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for NovaBay Pharmaceuticals.

Are investors shorting NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals saw a drop in short interest in January. As of January 31st, there was short interest totalling 410,200 shares, a drop of 20.1% from the January 15th total of 513,700 shares. Based on an average daily trading volume, of 549,100 shares, the days-to-cover ratio is currently 0.7 days. Currently, 2.5% of the company's shares are short sold. View NovaBay Pharmaceuticals' Current Options Chain.

Who are some of NovaBay Pharmaceuticals' key competitors?

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Opko Health (OPK), Achillion Pharmaceuticals (ACHN), AEterna Zentaris (AEZS), Catalyst Pharmaceuticals (CPRX), CorMedix (CRMD), SLS International (SLS), Arbutus Biopharma (ABUS), Agenus (AGEN), Amarin (AMRN) and AVEO Pharmaceuticals (AVEO).

Who are NovaBay Pharmaceuticals' key executives?

NovaBay Pharmaceuticals' management team includes the folowing people:
  • Mr. Justin M. Hall, Interim Pres, CEO, Gen. Counsel & Corp. Sec. (Age 41)
  • Mr. Jason Philip Raleigh, Interim CFO, Treasurer & Corp. Controller (Age 42)
  • Dr. David W. Stroman, Sr. VP of Ophthalmic Product Devel. & Chair of Ophthalmology Advisory Board (Age 74)

Who are NovaBay Pharmaceuticals' major shareholders?

NovaBay Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.76%) and Virtu Financial LLC (0.26%). Company insiders that own NovaBay Pharmaceuticals stock include Mijia Wu and Pharma (Hong Kong) Co Pioneer. View Institutional Ownership Trends for NovaBay Pharmaceuticals.

Which major investors are selling NovaBay Pharmaceuticals stock?

NBY stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have sold NovaBay Pharmaceuticals company stock in the last year include Mijia Wu and Pharma (Hong Kong) Co Pioneer. View Insider Buying and Selling for NovaBay Pharmaceuticals.

Which major investors are buying NovaBay Pharmaceuticals stock?

NBY stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. View Insider Buying and Selling for NovaBay Pharmaceuticals.

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is NovaBay Pharmaceuticals' stock price today?

One share of NBY stock can currently be purchased for approximately $0.59.

How big of a company is NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals has a market capitalization of $16.46 million. NovaBay Pharmaceuticals employs 70 workers across the globe.View Additional Information About NovaBay Pharmaceuticals.

What is NovaBay Pharmaceuticals' official website?

The official website for NovaBay Pharmaceuticals is http://novabay.com/.

How can I contact NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800.


MarketBeat Community Rating for NovaBay Pharmaceuticals (NYSEAMERICAN NBY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  207 (Vote Underperform)
Total Votes:  439
MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote "Outperform" if you believe NBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel